Literature DB >> 23269384

Genetic basis of differences in myxospore count between whirling disease-resistant and susceptible strains of rainbow trout.

Eric R Fetherman1, Dana L Winkelman, George J Schisler, Michael F Antolin.   

Abstract

We used a quantitative genetics approach and estimated broad sense heritability (h2b) of myxospore count and the number of genes involved in myxospore formation to gain a better understanding of how resistance to Myxobolus cerebralis, the parasite responsible for whirling disease, is inherited in rainbow trout Oncorhynchus mykiss. An M. cerebralis-resistant strain of rainbow trout, the German Rainbow (GR), and a wild, susceptible strain of rainbow trout, the Colorado River Rainbow (CRR), were spawned to create 3 intermediate crossed populations (an F1 cross, F2 intercross, and a B2 backcross between the F1 and the CRR). Within each strain or cross, h2b was estimated from the between-family variance of myxospore counts using full-sibling families. Estimates of h2b and average myxospore counts were lowest in the GR strain, F1 cross, and F2 intercross (h2b = 0.34, 0.42, and 0.34; myxospores fish-1 = 275, 9566, and 45780, respectively), and highest in the B2 backcross and CRR strain (h2b = 0.93 and 0.89; myxospores fish-1 = 97865 and 187595, respectively). Comparison of means and a joint-scaling test suggest that resistance alleles arising from the GR strain are dominant to susceptible alleles from the CRR strain. Resistance was retained in the intermediate crosses but decreased as filial generation number increased (F2) or backcrossing occurred (B2). The estimated number of segregating loci responsible for differences in myxospore count in the parental strains was 9 ± 5. Our results indicate that resistance to M. cerebralis is a heritable trait within these populations and would respond to either artificial selection in hatcheries or natural selection in the wild.

Entities:  

Mesh:

Year:  2012        PMID: 23269384     DOI: 10.3354/dao02543

Source DB:  PubMed          Journal:  Dis Aquat Organ        ISSN: 0177-5103            Impact factor:   1.802


  7 in total

1.  Serine protease inhibitors of the whirling disease parasite Myxobolus cerebralis (Cnidaria, Myxozoa): Expression profiling and functional predictions.

Authors:  Edit Eszterbauer; Dóra Szegő; Krisztina Ursu; Dóra Sipos; Ákos Gellért
Journal:  PLoS One       Date:  2021-03-29       Impact factor: 3.240

2.  Parental genetic diversity of brown trout (Salmo trutta m. fario) brood stock affects offspring susceptibility to whirling disease.

Authors:  Edit Eszterbauer; Barbara Forró; Zoltán Tolnai; Csaba Ferenc Guti; Gergely Zsigmond; György Hoitsy; Dennis Marc Kallert
Journal:  Parasit Vectors       Date:  2015-03-03       Impact factor: 3.876

3.  A RNAi-based therapeutic proof of concept targets salmonid whirling disease in vivo.

Authors:  Subhodeep Sarker; Simon Menanteau-Ledouble; Mohamed H Kotob; Mansour El-Matbouli
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

4.  Dual resistance to Flavobacterium psychrophilum and Myxobolus cerebralis in rainbow trout (Oncorhynchus mykiss, Walbaum).

Authors:  Brian W Avila; Dana L Winkelman; Eric R Fetherman
Journal:  J Fish Dis       Date:  2022-03-08       Impact factor: 2.580

5.  Survival and reproduction of Myxobolus cerebralis-resistant rainbow trout introduced to the Colorado river and increased resistance of age-0 progeny.

Authors:  Eric R Fetherman; Dana L Winkelman; Melinda R Baerwald; George J Schisler
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

6.  Susceptibility-related differences in the quantity of developmental stages of Myxobolus spp. (Myxozoa) in fish blood.

Authors:  Dóra Sipos; Krisztina Ursu; Ádám Dán; Dávid Herczeg; Edit Eszterbauer
Journal:  PLoS One       Date:  2018-09-21       Impact factor: 3.240

7.  STAT3/SOCS3 axis contributes to the outcome of salmonid whirling disease.

Authors:  Mona Saleh; Adina Friedl; Mitaly Srivastava; Hatem Soliman; Christopher J Secombes; Mansour El-Matbouli
Journal:  PLoS One       Date:  2020-06-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.